[go: up one dir, main page]

EP0506814A1 - Nouveaux produits - Google Patents

Nouveaux produits

Info

Publication number
EP0506814A1
EP0506814A1 EP91901844A EP91901844A EP0506814A1 EP 0506814 A1 EP0506814 A1 EP 0506814A1 EP 91901844 A EP91901844 A EP 91901844A EP 91901844 A EP91901844 A EP 91901844A EP 0506814 A1 EP0506814 A1 EP 0506814A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
bond
derivative
fractions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91901844A
Other languages
German (de)
English (en)
Inventor
Rhona Mary Smithkline Banks
Simon Edward Smithkline Blanchflower
Christopher Smithkline Reading
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898928844A external-priority patent/GB8928844D0/en
Priority claimed from GB909024716A external-priority patent/GB9024716D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0506814A1 publication Critical patent/EP0506814A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/80—Penicillium

Definitions

  • the present invention relates to a novel microorganism and to parasiticidal compounds obtainable therefrom and synthetically.
  • marcfortines Compounds known as marcfortines are disclosed by Polonsky et al in J.Chem.Soc.Chem.Comm (1980) pp 601-602 (marcfortine A) and Tet. Letters (1981) Vol 22 pp 1977-1980 (marcfortine B and C). The compounds are metabolites of the fungus Penicillium rocrueforti.
  • Paraherquamide is a metabolite of the fungus Penicillium paraherquei. Also disclosed is its dihydro derivative, obtained by catalytic hydrogenation.
  • US-A-4866060 describes the use of marcofortines A, B, C as anti-parasitic agents.
  • US-A-4923867 discloses derivatives of the marcfortines and their use as antiparasitic agents.
  • EP-A-0301742 describes the use of paraherquamide and dihydroparaherquamide as antiparasitic agents.
  • EP-A-0354615 and EP-A-0390532 disclose derivatives of paraherquamide and their use as antiparasitic agents.
  • a first aspect of the invention provides Penicillium sp. IMI 332995, or a mutant thereof, more particularly in biologically pure form.
  • a second aspect of the invention provides compounds of formula (I):
  • X is oxygen or a bond
  • Y is a single bond or a double bond
  • R 1 is hydrogen or methyl
  • R 2 is hydrogen or hydroxy
  • n is 0 or 1; but excluding paraherquamide and dihydroparaherquamide.
  • a third aspect of the invention provides a compound of formula (II) :
  • This compound is believed to be a bio-precursor of paraherquamide and may be used as an intermediate in the synthesis of paraherquamide or derivatives thereof.
  • a fourth aspect of the invention provides a marcfortine or paraherquamide derivative of partial formula (III):
  • this aspect of the invention provides an N(12) oxide of a marcfortine or parherquamide or a derivative thereof (when the usual numbering for these compounds is used). Substitution at other positions is optional, but in the partial formula preferably occurs on the carbon atom at position 14, or the amide nitrogen atom.
  • the marcfortine derivative may be any of those disclosed in US-A-4923867, the disclosure of which is incorporated herein by reference.
  • the paraherquamide derivative may be any of those disclosed in EP-A-0301742, EP-A-0322937, EP-A-0354615 or EP-A-0390532, the disclosures of which are incorporated herein by reference.
  • the preferred N(12) oxide is VM55596, the N (12) oxide of paraherquamide itself.
  • the compound of formula (II) in which P is 0 (VM55599) is also obtainable as a metabolite of IMI 332995.
  • a further aspect of the invention provides a process for the production of compounds of formula (I) or formula (II), or a derivative thereof, which comprises cultivating Penicillium sp. IMI 332995, or a mutant thereof, and subsequently isolating the compound or derivative thereof from the culture.
  • the present invention also provides a process for the production of a compound of the invention or a derivative thereof, which comprises cultivating a producing microorganism, and subsequently isolating the compound or derivative thereof from the culture.
  • the present invention furthermore provides a process for the preparation of a compound of the invention or derivative thereof, which comprises chromatographically separating the compound or derivative thereof from a solution thereof in admixture with other substances into a fraction comprising the compound or derivative thereof and other fractions.
  • 'cultivation' means the deliberate aerobic growth of an organism in the presence of assimilable sources of carbon, nitrogen, sulphur and mineral salts. Such aerobic growth may take place in a solid or semi-solid nutritive medium, or in a liquid medium in which the nutrients are dissolved or suspended. The cultivation may take place on an aerobic surface or by submerged culture.
  • the nutritive medium may be composed of complex nutrients or may be chemically defined.
  • suitable microorganisms for use in the cultivation process according to the invention for the production of VM 55595 and/or VM 55596 and/or VM 55599 include strains of fungi belonging to the genus Penicillium that are capable of elaborating compounds according to the invention. It has further been found that Penicillium sp. IMI 332995, which has been isolated from soil, and also mutants and natural variants thereof, is particularly suitable for this purpose.
  • mutant strain which arises spontaneously or through the effect of an external agent whether that agent is applied deliberately or otherwise.
  • Suitable methods of producing mutant strains include those outlined by H.I.Adler in 'Techniques for the Development of Micro- organisms' in ''Radiation and Radioisotopes for Industrial Microorganisms'', Proceedings of a Symposium, Vienna, 1973, page 241, International Atomic Energy Authority, and these include:
  • Ionizing radiation e.g. X-rays and ⁇ -rays
  • u.v. light u.v. light plus a photosensitizing agent (e.g. 8-methoxypsoralen)
  • nitrous acid hydroxylamine
  • pyrimidine base analogues e.g. 5-bromouracil
  • acridines alkylating agents (e.g. mustard gas, ethyl-methane sulphonate), hydrogen peroxide, phenols, formaldehyde, nitrosoguanidine, heat, and
  • Penicillium sp. IMI 332995 is believed to comprise a previously unreported strain in the genus Penicillium. It has been deposited in the C.A.B. International Mycological Institute, Ferry Lane, Kew, Surrey, TW9 3AF, England, the deposit (IMI 332995/ filing date 31st May, 1989) being made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure.
  • Penicillium sp. IMI 332995 The characteristics of Penicillium sp. IMI 332995 were as follows:
  • Penicillium sp. IMI 332995 had produced colonies which were 20-30mm diameter. Margins of the colonies were low and velutinous, central areas were floccose; mycelium was mostly white in peripheral areas, at the centres yellow green to grey green. A yellow exudate was produced over the colony; reverse colour of colony was yellow brown.
  • Conidiophores were borne from subsurface or surface hyphae, stipes 100-300 x 2.2-3.0 ⁇ m, smooth walled, characteristically terminating in well defined verticils of 3-5 divergent metulae. Some subterminal or intercalary metulae were produced also. Metulae were usually of uniform length (12-18 x 2.2-2.5 ⁇ m), phialides were in compact verticils of 8-12, ampulliform usually with short collula; conidia were spheroidal to subspheroidal, 2.2-3.0 ⁇ m diam, with walls smooth or finely roughened, typically borne in long well defined columns, one per metula.
  • the fermentation medium for cultivating the producing organism may be solid, semisolid or liquid and suitably contains sources of assimilable carbon and assimilable nitrogen together with inorganic salts.
  • Suitable sources of nitrogen include yeast extract, soybean flour, meat extract, cottonseed flour, malt, distillers dried solubles, amino acids, protein hydrolysates and ammonium and nitrate nitrogen.
  • Suitable carbon sources include glucose, sucrose, lactose, maltose, starch and glycerol.
  • the culture medium also includes alkali metal ions (for example, sodium), alkaline earth metal ions (for example, magnesium), halogen ions (for example, chloride), and trace elements (for example, iron).
  • the cultivation may suitably be effected at a temperature of about 20 to 35°C, advantageously 27 to 28°C, and the culture may suitably be harvested after 2 to 35 days, advantageously about 5 to 20 days, after the initiation of fermentation in order to give an optimum yield of the desired compound.
  • the desired compound or derivative thereof may then be isolated from the culture medium and worked up and purified using conventional techniques.
  • the desired product may be obtained from either the mycelial growth or from the culture medium. It may therefore be convenient for the first isolation step to involve the separation of the mycelium from the culture medium by, for example, filtration or centrifugation of fermentation broth, to give a clarified culture filtrate and solid material. Alternatively, the whole medium including the mycelium can be extracted directly.
  • organic solvent extraction step in the isolation or purification procedure, suitably using a solvent such as acetone or chloroform.
  • the extract may contain additional substances, and therefore chromatographic separation may result in a plurality of fractions, of which the desired fraction or fractions is or are the fraction (s) comprising the desired compound or a derivative thereof.
  • the desired fraction (s) may readily be identified in a routine manner by testing for anthelmintic activity and/or by monitoring each fraction chromatographically.
  • the desired fraction (s) is/are that/those identified by such procedures as containing the desired compound or a derivative thereof.
  • chromatographic separation may be carried out in a routine manner.
  • the fractions containing the desired compound or a derivative thereof may be combined and then subjected to further purification steps.
  • the expression 'fraction consisting essentially of the desired compound or a derivative thereof means a fraction containing the desired compound or a derivative thereof as the sole component present in that fraction, or as the major component (whether other components are active or are inactive impurities) present in that fraction.
  • the expression 'major component' means the component that is present in the greatest amount relative to other individual components (exclusive of solvent).
  • the major component is present in an amount greater than the sum of the amounts of all other components (excluding solvent).
  • the major component is present in an amount of at least 60%, advantageously at least 70%, preferably at least 80%, especially from 90% to 100%, by weight, relative to the total amount of active material, or relative to the total amount of material whether active or inactive (exclusive of solvent), as the case may be, present in the fraction.
  • the compounds of formula (I) are produced in admixture with one another, so that fractions may be obtained which consist essentially of a mixture of two or more compounds of formula (I).
  • VM 55596 may be prepared by the N-oxidation of paraherquamide. A suitable procedure is described in J. Org. Chem. [1970] 35, 1721 et seq. The same procedure may be used to prepare the compound of formula (II) in which p is 0 by N-oxidation of VM 55599. Similarly compounds of partial formula (III) can be obtained by N-oxidation of the derivatives disclosed in the patents incorporated herein by reference.
  • the present invention provides a method for the production of a compound of partial formula (III) which comprises reacting a marcfortine or paraherquamide on derivative thereof of partial formula (IV)
  • the N-oxide is formed by reaction with a percarboxylic acid in an appropriate solvent.
  • a percarboxylic acid Most suitably an aromatic peracid in a non-polar solvent is used, since the reaction may usually be carried out at room temperature.
  • Suitable aromatic peracids include perbenzoic acid, chloroperbenzoic acid perphthalic acid.
  • the reaction is carried out in chloroform using m-chloroperbenzoic acid.
  • peracetic acid is the most common reagent, but is less suitable in view of the more adverse conditions, such as heating the heterocyclic compound with glacial acetic acid and hydrogen peroxide at temperatures from 20 to 90°C.
  • Compounds of formula (I) that are not obtainable as metabolites of IMI 332995, or by N-oxidation as described above, may be prepared by chemical modification of compounds that are obtainable as metabolites, using substitution techniques that are well known in organic chemistry, for example for a alkylation of amide nitrogens.
  • the dihydro derivatives of the compounds of formula (I) may be prepared from the compounds of formula (I) in which Y is a double bond using the procedure described in Example 11 of EP-A-0 301742, referred to above.
  • the compound or mixture of compounds according to the invention is suitably provided in substantially pure form, for example at least 50% pure, suitably at least 60% pure, advantageously at least 75% pure, preferably at least 85%
  • An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.
  • the compounds of the invention have parasiticidal properties, for example against nematodes such as Trichostrongylus colubriformis, and are useful for the treatment of helminthiasis in animals such as mammals, including humans and domesticated animals (including farm animals).
  • nematodes such as Trichostrongylus colubriformis
  • the present invention also provides a compound according to the invention, for use in the treatment of the human or animal body, especially for treating endo- and ectoparasitic infestations and particularly for treating helminthiasis of domestic and farm animals.
  • helminthiasis encompasses those diseases of man and animals caused by infestation with parasitic worms such as Strongyles, Ascarids, hookworms lungworms, filarial worms, whipworms, and liver flukes.
  • parasitic worms such as Strongyles, Ascarids, hookworms lungworms, filarial worms, whipworms, and liver flukes.
  • the compound may also be used against nematodes occurring in the soil or parasitic to plants.
  • the compounds of the invention are also active against Arthropods.
  • the phylum Arthropoda comprises insects - such as biting flies, lice, bugs, beetles and fleas - and arachnids - such as mites and ticks.
  • a broad aspect of the invention provides a method of eradicating arthropod or nematode infestations, which method comprises applying a compound according to the invention or a derivative thereof to the arthropods or nematodes or to their environment .
  • the present invention thus provides a pesticidal composition
  • a pesticidal composition comprising a compound according to the invention or a derivative thereof together with a suitable carrier or excipient, such as an aerosol formulation.
  • the present invention also provides a pharmaceutical or veterinary composition
  • a pharmaceutical or veterinary composition comprising a compound according to the invention or a pharmaceutically acceptable deriaative thereof together with a pharmaceutically or veterinarily acceptable carrier or excipient.
  • the present invention also provides a method of treatment or prophylaxis of endo- and ectoparasitic infestations, especially helminthiasis, of animals, especially humans and domesticated mammals, which comprises administering an effective non-toxic amount of a compound according to the invention or a pharmaceutically acceptable derivative thereof, or a composition according to the invention, to a patient in need thereof.
  • composition according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other anthelmintics.
  • the drug may be administered to animals orally (as a paste, drench, bolus, capsule or tablet), parenterally, percutaneously, as a food additive (eg granules, pellets or powder), or may be prepared as an aerosol spray formulation.
  • the compounds of the invention may be formulated as a mixture with each other and/or with other anthelmintics, insecticides, acaricides or other pharmacologically active substances.
  • composition consists of sufficient material to provide a dose of from 0.01 to 50mg of active ingredient per kg of animal body weight per dose, more suitably 0.1 to 10mg/kg per dose.
  • a composition according to the invention may suitably contain from 0.001 to 99% by weight of the compound according to the invention (based on the total weight of the composition) depending on the method of administration.
  • the crude fermentation broth may be administered, for example by incorporating the freeze-dried fermentation broth into the feed of the animal.
  • a conidial suspension of Penicillium sp. IMI 332995 was prepared in phosphate buffered saline containing 10% glycerol and 1% Tween 80 (PBSGT) from a well grown potato dextrose agar* p late culture.
  • PBSGT phosphate buffered saline containing 10% glycerol and 1% Tween 80
  • the primary purification was by preparative reverse phase HPLC (Dynamax - 60A C-18 column 41.4 x 250mm, Rainin
  • VM 54159 and VM 55594 eluted as adjacent peaks (43-44 mins and 45-49 mins respectively) being distinguished on the basis of UV ⁇ max of the spectral scans (VM 54159 ⁇ max 226nm, VM 55594 ⁇ max 244nm).
  • VM55595 eluted as a discrete peak at 59-65 mins ( ⁇ max 244nm) obtained after evaporation of solvent.
  • Example 1 Culture IMI 332995, grown for 24 days on 10L Czapek Dox agar (Example 1), was harvested into acetone and extracted into chloroform, as described in Example 1, to produce 5.1 g of extract.
  • This extract was divided into 2 aliquots, I and II (containing approximately 4 and 1 g respectively). Each was chromatographed by preparative reverse phase HPLC (Dynamax - 60A C-18 41.4 x 250 mm, Rainin Instrument Co., USA), eluted with methanol:water (75:25) at 15 ml/min. 15 ml fractions were collected throughout and an aliquot of each was examined by TLC (Merck glass-backed silica gel 60 plates, 20 x 20 cm, developed with 90:10 chloroformrmethanol, visualised by spraying with Ehrlichs reagent, and heating). Fractions containing the major Ehrlichs positive component in each run (corresponding to fraction A in Example 1) were combined (fractions 9-24 in run I and 7-14 in run II) and concentrated to dryness under vacuum to yield 1.93 g.
  • the column was monitored by UV absorbance (235 and 244 nm, 1,000S Diode Array Detector, Applied Biosystems Limited, Warrington, UK), and each fraction examined by TLC as before. Paraherquamide-rich material eluted in fractions 34-37. Fractions 110-115, corresponding to a peak in UV absorbance and an Ehrlichs positive spot on TLC (Rf 0.19) were pooled and combined with the corresponding fractions (by TLC) from the other column run (which was identical except that the 97:3 isocratic elution was continued for 60 minutes).
  • VM 55596 was the N-oxide derivative of paraherquamide
  • TPP triphenylphosphene
  • a conidial suspension of Penicillium sp. IMI 332995 was prepared in phosphate buffered saline containing 10% glycerol and 1% Tween 80 (PBSGT) from a well grown culture on a potato dextrose agar (Oxoid Ltd. Basingstoke, UK) plate. 2-3mls of suspension were spread onto Czapek Dox agar plates and incubated at 28°C.
  • PBSGT phosphate buffered saline containing 10% glycerol and 1% Tween 80
  • the acetone was evaporated under vacuum yielding an aqueous residue which was then extracted, four times, each with 2.5 volumes of chloroform.
  • the organic phase was separated and evaporated under vacuum to leave 3.64 g and 11.15 g of yellow oil from the two batches, which were then combined.
  • the combined extract was suspended in approximately 200 ml of methanol which caused a white precipitate to form. This was filtered off and rinsed with 50 ml of methanol.
  • the precipitated material was resuspended in approximately 200 ml of warm (30°C) methanol and again filtered. The precipitate was discarded and the methanolic solutions pooled and the solvent evaporated to leave 9.44 g of material.
  • the sample was suspended in 50 ml of 7:3 methanol/water and applied to the top of the column which was then eluted as follows, 500 ml fractions were collected throughout.
  • Sample 'G1' was further chromatographed by normal phase HPLC using a Dynaxax 60A Si column 10 x 250 mm eluted with hexane/pro ⁇ an-2-ol pumped at 4 ml/min.
  • the solvent composition was as follows: 0-18 min Isocratic, 98:2 hexane/pro ⁇ an-2-ol; 18-88 min linear gradient 98:2 to
  • the product VM 55599 was characterized as follows:-
  • Mass spectrometry (E1 and FAB) indicated a molecular weight of 349.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composés apparentés à la paraherquamide préparés par culture de Penicillium sp. IMI 332995. La présente invention décrit en outre une méthode synthétique de préparation des N-oxydes de dérivés de paraherquamide.
EP91901844A 1989-12-21 1990-12-20 Nouveaux produits Withdrawn EP0506814A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8928844 1989-12-21
GB898928844A GB8928844D0 (en) 1989-12-21 1989-12-21 Novel compounds
GB909024716A GB9024716D0 (en) 1990-11-14 1990-11-14 Novel products
GB9024716 1990-11-14

Publications (1)

Publication Number Publication Date
EP0506814A1 true EP0506814A1 (fr) 1992-10-07

Family

ID=26296401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91901844A Withdrawn EP0506814A1 (fr) 1989-12-21 1990-12-20 Nouveaux produits

Country Status (6)

Country Link
EP (1) EP0506814A1 (fr)
JP (1) JPH05502163A (fr)
CA (1) CA2071982A1 (fr)
IE (1) IE904606A1 (fr)
PT (1) PT96298A (fr)
WO (1) WO1991009961A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134936B2 (ja) * 1992-10-16 2001-02-13 沖電気工業株式会社 衝撃センサ
TW410227B (en) * 1993-06-16 2000-11-01 Upjohn Co 14-substituted marcfortines and derivatives useful as antiparasitic agents
TW334436B (en) * 1995-07-21 1998-06-21 Upjohn Co Antiparasitic marcfortines and paraherquamides
ZA976761B (en) * 1996-09-09 1999-01-29 Upjohn Co 25 Methylene and 24,25-epoxy marcfortines and paraherquamides
WO1998021211A1 (fr) * 1996-11-15 1998-05-22 Pharmacia & Upjohn Company Marcfortines et paraherquamides substitues en position 1 et 2 utilises comme antiparasitaires
ES2729854T3 (es) 2008-11-14 2019-11-06 Merial Inc Compuestos de ariloazol-2-ilcianoetilamino parasiticidas enriquecidos enantioméricamente
BRPI0922043B1 (pt) 2008-11-19 2019-04-24 Merial, Inc. Composições compreendendo um aril pirazol e/ou formamidina, métodos e usos das mesmas
JP5595412B2 (ja) 2008-12-04 2014-09-24 メリアル リミテッド 二量体アベルメクチン及びミルベマイシン誘導体
BR112012013482B1 (pt) 2009-12-04 2018-11-06 Basf Se compostos de bis-organossulfurados pesticidas
BR112012014933B1 (pt) 2009-12-17 2020-10-27 Merial, Inc. composições que compreendem compostos lactonas macrocíclicas e spirodioxepinoindóis
PT2513104E (pt) 2009-12-17 2016-06-03 Merial Inc Compostos de di-hidroazole antiparasitários e composições que compreendem os mesmos
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
US8822528B2 (en) 2010-11-16 2014-09-02 Merial Limited Monensin derivatives for the treatment and prevention of protozoal infections
WO2013003505A1 (fr) 2011-06-27 2013-01-03 Merial Limited Composés et compositions d'amidopyridyléther et leur utilisation contre des parasites
WO2013003168A1 (fr) 2011-06-27 2013-01-03 Merial Limited Dérivés insectifuges inédits de coumarine, leur synthèse et leurs procédés d'utilisation
KR20200019793A (ko) 2011-09-12 2020-02-24 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 이속사졸 활성화제를 포함하는 구충 조성물, 이의 용도 및 구충 방법
WO2013044118A2 (fr) 2011-09-23 2013-03-28 Merial Limited Modélisation indirecte de molécules répulsives inédites actives contre les insectes, les acariens et autres arthropodes
WO2013074892A1 (fr) 2011-11-17 2013-05-23 Merial Limited Compositions comprenant un aryl pyrazole et un imidazole substitué, procédés et utilisations de celles-ci
HUE067125T2 (hu) 2011-12-02 2024-10-28 Boehringer Ingelheim Vetmedica Gmbh Hosszú hatású injektálható moxidektin formulációk
UA119843C2 (uk) 2012-02-06 2019-08-27 Меріал, Інк Паразитицидні пероральні ветеринарні композиції, що включають системно діючі активні агенти, способи та застосування цих композицій і способів
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
SG10201700291VA (en) 2012-04-20 2017-03-30 Merial Inc Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
SI2922845T1 (sl) 2012-11-20 2018-10-30 Merial, Inc. Antihelmintske spojine in sestavki ter postopek za njihovo uporabo
PL3063144T3 (pl) 2013-11-01 2022-01-31 Boehringer Ingelheim Animal Health USA Inc. Przeciwpasożytnicze i szkodniczobójcze związki izoksazolinowe
WO2015161224A1 (fr) 2014-04-17 2015-10-22 Merial, Inc. Utilisation de composés de malononitrile pour protéger des animaux contre les parasites
ES2842592T3 (es) 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
EA030459B1 (ru) 2014-06-19 2018-08-31 Мериал, Инк. Паразитицидные композиции, содержащие индольные производные, способы их получения и их применение
AU2015339096B2 (en) 2014-10-31 2018-08-02 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal composition comprising fipronil
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG10202103403SA (en) 2015-05-20 2021-05-28 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic depsipeptide compounds
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2018039508A1 (fr) 2016-08-25 2018-03-01 Merial, Inc. Procédé de réduction d'effets indésirables dans des traitements antiparasitaires
WO2018071535A1 (fr) 2016-10-14 2018-04-19 Merial, Inc. Composés de vinyl-isoxazoline pesticides et parasiticides
MX2019005628A (es) 2016-11-16 2019-12-18 Boehringer Ingelheim Animal Health Usa Inc Compuestos depsipeptidos antihelminticos.
CN111194316A (zh) 2017-08-14 2020-05-22 勃林格殷格翰动物保健美国公司 农药的和杀寄生物的吡唑-异噁唑啉化合物
US11583545B2 (en) 2018-02-08 2023-02-21 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
US12269822B2 (en) 2018-07-09 2025-04-08 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
EP3883648A1 (fr) 2018-11-20 2021-09-29 Boehringer Ingelheim Animal Health USA Inc. Composé indazolylcyanoéthylamino, compositions associées, procédé de fabrication et procédés d'utilisation de celui-ci
JP2022522200A (ja) 2019-03-01 2022-04-14 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 注射用クロルスロン組成物、その方法および使用
CR20210477A (es) 2019-03-19 2022-01-06 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
CR20220665A (es) 2020-05-29 2023-07-19 Boehringer Ingelheim Pharma Compuestos heterocíclicos como anthelmínticos
EP4262789A1 (fr) 2020-12-21 2023-10-25 Boehringer Ingelheim Vetmedica GmbH Collier parasiticide comprenant des composés d'isoxazoline
US12258193B2 (en) 2022-02-17 2025-03-25 Boehringer Ingelheim Vetmedica Gmbh Method and system for providing a fluid product mailer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075307A (en) * 1987-07-28 1991-12-24 Merck & Co., Inc. Paraherquamide and dihydroparaherquamide as antihelminthic agents
US4873247A (en) * 1987-11-27 1989-10-10 Goegelman Robert T Derivatives of paraherquamide isolated from a fermentation broth active as antiparasitic agents
US4978656A (en) * 1988-08-12 1990-12-18 Merck & Co., Inc. Synthetic derivatives of paraherquamide
US4866060A (en) * 1988-08-19 1989-09-12 Merck & Co., Inc. Use of the natural product marcfortines as antiparasitic agents
US4923867A (en) * 1988-08-24 1990-05-08 Merck & Co., Inc. Synthetic marcfortine derivatives useful as antiparasitic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9109961A2 *

Also Published As

Publication number Publication date
CA2071982A1 (fr) 1991-06-22
JPH05502163A (ja) 1993-04-22
WO1991009961A3 (fr) 1991-10-31
IE904606A1 (en) 1991-07-03
PT96298A (pt) 1991-09-30
WO1991009961A2 (fr) 1991-07-11

Similar Documents

Publication Publication Date Title
EP0506814A1 (fr) Nouveaux produits
WO1992022555A1 (fr) Derives de paraherquamide, precurseur de ces derives, procedes de preparation, microorganisme utilise et utilisation de ces derives comme agents parasiticides
EP0254583B1 (fr) Dérivés de la milbémycine à activité parasiticide, un procédé pour leur préparation et les compositions les contenant
US5614546A (en) Antiparasitic agents
AU713634B2 (en) Antiparasitic agents
CA2038450A1 (fr) Inhibiteurs des synthetases des squalenes.
IE920782A1 (en) Cyclic Ketal Derivatives
CZ261493A3 (en) Pharmacologically active compounds, process of their preparation and pharmaceutical preparations in which they are comprised
EP0126092A1 (fr) Antibiotiques a base de xenorhabdines
EP0358418B1 (fr) Peptide cyclique, sa préparation et son utilisation pour le traitement de troubles cardiovasculaires
EP0478061A1 (fr) Agent antiviral
US7375230B2 (en) Fermentation and purification of migrastatin and analog
CA2012013C (fr) Antibiotique bmy-41339 antimoral
EP0325462A2 (fr) Dérivés de la milbémycine à activité anthelmintique
IE44992B1 (en) 3-hydroxyalkyl (or acetylalkyl)-6,6a,7,8,10,10a-hexahydro -9h-dibenzo(b,d)pyran derivatites
US5254727A (en) Acyclic tricarboxylic acid compounds
US5100921A (en) Angucyclinones from streptomycetes, a process for the preparation thereof, and the use thereof
US4861775A (en) Pharmacological use of phenoxazinones
US5137813A (en) Process for production of an antibiotic compound using zalerion arboricola
IE60755B1 (en) Macrolide compound
JPH07145161A (ja) 新規セスキテルペン誘導体
US5086045A (en) Antitumor antibiotic
JP2002142795A (ja) 新規活性物質、その製造法および用途
KR100427411B1 (ko) 아스퍼질러스 속 Ｆ７０６０９（ＫＣＴＣ１８０５５Ｐ）와 β－글루코시다제 저해제
US5712151A (en) Antifungal agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940701